233 related articles for article (PubMed ID: 9118042)
21. Ki-ras gene mutations are invariably present in low-grade mucinous tumors of the vermiform appendix.
Zauber P; Berman E; Marotta S; Sabbath-Solitare M; Bishop T
Scand J Gastroenterol; 2011 Jul; 46(7-8):869-74. PubMed ID: 21443421
[TBL] [Abstract][Full Text] [Related]
22. K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study.
Høgdall EV; Høgdall CK; Blaakaer J; Christensen L; Bock JE; Vuust J; Glud E; Kjaer SK;
Gynecol Oncol; 2003 Apr; 89(1):31-6. PubMed ID: 12694651
[TBL] [Abstract][Full Text] [Related]
23. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.
Hunter SM; Gorringe KL; Christie M; Rowley SM; Bowtell DD; ; Campbell IG
Clin Cancer Res; 2012 Oct; 18(19):5267-77. PubMed ID: 22891197
[TBL] [Abstract][Full Text] [Related]
24. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
25. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
26. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
Caduff RF; Svoboda-Newman SM; Ferguson AW; Johnston CM; Frank TS
Am J Surg Pathol; 1999 Mar; 23(3):323-8. PubMed ID: 10078924
[TBL] [Abstract][Full Text] [Related]
27. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
Rodríguez IM; Prat J
Am J Surg Pathol; 2002 Feb; 26(2):139-52. PubMed ID: 11812936
[TBL] [Abstract][Full Text] [Related]
28. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin.
Werness BA; DiCioccio RA; Piver MS
Hum Pathol; 1997 May; 28(5):626-30. PubMed ID: 9158713
[TBL] [Abstract][Full Text] [Related]
29. Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.
Morita K; Ono Y; Fukui H; Tomita S; Ueda Y; Terano A; Fujimori T
Pathol Int; 2000 Mar; 50(3):219-23. PubMed ID: 10792785
[TBL] [Abstract][Full Text] [Related]
30. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.
Diebold J; Seemüller F; Löhrs U
Lab Invest; 2003 Feb; 83(2):251-8. PubMed ID: 12594239
[TBL] [Abstract][Full Text] [Related]
31. Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints.
Versa-Ostojić D; Stanković T; Stemberger-Papić S; Vrdoljak-Mozetic D; Manestar M; Krasević M
Anal Quant Cytol Histol; 2008 Jun; 30(3):160-8. PubMed ID: 18630841
[TBL] [Abstract][Full Text] [Related]
32. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas.
Sugio K; Kishimoto Y; Virmani AK; Hung JY; Gazdar AF
Cancer Res; 1994 Nov; 54(22):5811-5. PubMed ID: 7954406
[TBL] [Abstract][Full Text] [Related]
33. P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas.
Mueller J; Gansauge S; Mattfeldt T
Hepatogastroenterology; 2003; 50(50):541-4. PubMed ID: 12749268
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases.
Lee KH; Lee JS; Suh C; Kim SW; Kim SB; Lee JH; Lee MS; Park MY; Sun HS; Kim SH
Cancer; 1995 Jun; 75(12):2794-801. PubMed ID: 7773929
[TBL] [Abstract][Full Text] [Related]
35. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
36. K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.
Alvarez AA; Moore WF; Robboy SJ; Bentley RC; Gumbs C; Futreal PA; Berchuck A
Gynecol Oncol; 2001 Feb; 80(2):201-6. PubMed ID: 11161860
[TBL] [Abstract][Full Text] [Related]
37. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
[TBL] [Abstract][Full Text] [Related]
38. Immunophenotype and K-RAS mutation in mucinous ovarian adenocarcinoma with mural nodule of high-grade sarcoma: case report.
Desouki MM; Fadare O; Kanbour A; Kanbour-Shakir A
Int J Gynecol Pathol; 2014 Mar; 33(2):186-90. PubMed ID: 24487474
[TBL] [Abstract][Full Text] [Related]
39. [Studies on the point mutation of ras oncogene in ovarian tumor].
Fujimoto I; Shimizu Y; Umezawa S; Katase K; Hirai Y; Yamauchi K; Hasumi K
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Nov; 45(11):1289-96. PubMed ID: 8258728
[TBL] [Abstract][Full Text] [Related]
40. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
